UMich Spinout Lycera Nets $36M in VC Cash; Taps NYU Immunologist for New Research Program

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.